Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BST-236 in adults with relapsed or refractory AML or MDS unfit for intensive chemotherapy
MOH_2022-03-14_010595Phase 2Active, not recruiting
- Sponsor
- BioSight
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aspacytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by BioSight. Started Feb 2022; status: active, not recruiting.
02
Drugs
aspacytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2022-03-14_010595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-14_010595.